Key Takeaways Regeneron shares were lower ahead of the opening bell Thursday morning after the DOJ filed a complaint accusing the drugmaker of manipulating Medicare’s drug pricing process. The DOJ Alleges the company failed to report credit card fees that it paid distributors. Regeneron shares may find support around $915 from a nine-month trendline. A breakdown below this level could see a retest of a key horizontal line near$835. Shares in biotech giant Regeneron Pharmaceuticals (REGN) go under the micro ...